[HTML][HTML] Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies
E Vosoughi, JM Lee, JR Miller, M Nosrati, DR Minor… - BMC cancer, 2018 - Springer
Background Melanoma brain metastasis is associated with an extremely poor prognosis,
with a median overall survival of 4–5 months. Since 2011, the overall survival of patients …
with a median overall survival of 4–5 months. Since 2011, the overall survival of patients …
[HTML][HTML] Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies
E Vosoughi, JM Lee, JR Miller, M Nosrati, DR Minor… - BMC Cancer, 2018 - ncbi.nlm.nih.gov
Background Melanoma brain metastasis is associated with an extremely poor prognosis,
with a median overall survival of 4–5 months. Since 2011, the overall survival of patients …
with a median overall survival of 4–5 months. Since 2011, the overall survival of patients …
Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies.
E Vosoughi, JM Lee, JR Miller, M Nosrati, DR Minor… - BMC Cancer, 2018 - europepmc.org
Background Melanoma brain metastasis is associated with an extremely poor prognosis,
with a median overall survival of 4-5 months. Since 2011, the overall survival of patients with …
with a median overall survival of 4-5 months. Since 2011, the overall survival of patients with …
Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies
E Vosoughi, JM Lee, JR Miller, M Nosrati, DR Minor… - BMC Cancer, 2018 - go.gale.com
Background Melanoma brain metastasis is associated with an extremely poor prognosis,
with a median overall survival of 4-5 months. Since 2011, the overall survival of patients with …
with a median overall survival of 4-5 months. Since 2011, the overall survival of patients with …
[HTML][HTML] Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies
E Vosoughi, JM Lee, JR Miller… - BMC …, 2018 - bmccancer.biomedcentral.com
Melanoma brain metastasis is associated with an extremely poor prognosis, with a median
overall survival of 4–5 months. Since 2011, the overall survival of patients with stage IV …
overall survival of 4–5 months. Since 2011, the overall survival of patients with stage IV …
Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies
E Vosoughi, JM Lee, JR Miller, M Nosrati… - BMC …, 2018 - pubmed.ncbi.nlm.nih.gov
Background Melanoma brain metastasis is associated with an extremely poor prognosis,
with a median overall survival of 4-5 months. Since 2011, the overall survival of patients with …
with a median overall survival of 4-5 months. Since 2011, the overall survival of patients with …
[PDF][PDF] Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies
E Vosoughi, JM Lee, JR Miller, M Nosrati, DR Minor… - 2018 - bmccancer.biomedcentral.com
Background: Melanoma brain metastasis is associated with an extremely poor prognosis,
with a median overall survival of 4–5 months. Since 2011, the overall survival of patients …
with a median overall survival of 4–5 months. Since 2011, the overall survival of patients …